The metastasis-promoting effects of E2 and P4 treatment, the increased invasiveness of PR overexpressing tumors together with the genetic evidence that PR is required independently of ER for in vivo tumor growth of patient-derived cells argues that PR may be an important protein to target in ER + BC. Here, ESR1 is linked to neoplasm.